ArticleCureus2024
Supratherapeutic International Normalized Ratio in a Patient on Warfarin Following Initiation of Brexpiprazole Pharmacotherapy: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many medications have established interactions with warfarin, potentially affecting international normalized ratio (INR) levels and increasing the risk of bleeding complications. We present the case of a 74-year-old female inpatient with late-onset schizophrenia who was initiated on brexpiprazole while concurrently receiving warfarin therapy for a ventricular thrombus. Despite INR levels being within a range of 1.8 to 2.7 prior to brexpiprazole initiation, the patient's INR increased sharply to 6 within five days, leading to a potential gastrointestinal bleed that required medical admission. While the manufacturer's in-vitro studies suggest that brexpiprazole does not displace warfarin from albumin, both drugs exhibit greater than 99% protein binding. This case highlights the critical need for close monitoring of INR levels when initiating brexpiprazole in patients on warfarin therapy, due to the potential for warfarin displacement from plasma proteins and subsequent bleeding complications. This interaction warrants further exploration, and clinicians should exercise caution when using these medications concomitantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.